Conversion to Sirolimus in Pediatric Renal Transplantation Recipients

Transplantation Proceedings

Volumn 38, Issue 6, 2006, Pages 1901-1903

  Garcia, C D ^a   Bittencourt, V B ^a   Alves, A B ^a   Garcia, V D ^a   Tumelero, A ^a   Antonello, J S ^a   Malheiros, D ^a  

^a Santa Casa de Porto Alegre   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; GRAFT RECIPIENT; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEOPLASM; NEPHROTOXICITY; PEDIATRIC SURGERY; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES; SAFETY; SIROLIMUS; TREATMENT OUTCOME;

EID: 33746924485     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.06.063     Document Type: Article

References (25)

1. Gupta P., Kaufman S., and Fishbein T.M. Sirolimus for solid organ transplantation in children. Pediatr Transplant 9 (2005) 269
2. Liu K.L., Chu S.H., Chiang Y.J., et al. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation. an initial experience in Taiwan. Transplant Proc 36 (2004) 2051
3. Chueh S.C., and Kahan B.D. Clinical application of sirolimus in renal transplantation. an update. Transpl Int 18 (2005) 261
4. Wu M.S., Chang C.T., and Hung C.C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 19 (2005) 236
5. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
6. Peddi V.R., Jensik S., Pescovitz M., et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 19 (2005) 130
7. Egidi M.F., Cowan P.A., Naseer A., et al. Conversion to sirolimus in solid organ transplantation. a single-center experience. Transplant Proc 35 suppl 3 (2003) 131S
8. Vester U., Kranz B., Nadalin S., et al. Sirolimus rescue of renal failure in children after combined liver-kidney transplantation. Pediatr Nephrol 20 (2005) 686
9. Kahan B.D. Sirolimus-based immunosuppression. present state of the art. J Nephrol 17 suppl 8 (2004) S32
10. Koehl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319
11. Rao R.D., Buckner J.C., and Sarkaria J.N. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4 (2004) 621
12. Garcia V.D., Bonamigo Filho J.L., Neumann J., et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 16 (2003) 202
13. Zaltzman J.S., Prasad R., Chun K., et al. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 20 (2005) 1748
14. Al-Akash S.I., Al Makadma A.S., and Al Omari M.G. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9 (2005) 249
15. Lipshutz G.S., Flechner S.M., Govani M.V., et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 4 (2004) 2132
16. Wali R.K., Drachenberg C., Hirsch H.H., et al. BK virus-associated nephropathy in renal allograft recipients. rescue therapy by sirolimus-based immunosuppression. Transplantation 78 (2004) 1069
17. Robson M., Cote I., Abbs I., et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression. potentiation of calcineurin-inhibitor-induced endothelial damage?. Am J Transplant 3 (2003) 324
18. Franco A., Hernandez D., Capdevilla L., et al. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors. role of sirolimus. Transplant Proc 35 (2003) 1764
19. Keane W.F., and Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE). a position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004
20. Wlodarczyk Z., Vitko S., Salmela K., et al. Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. Transplant Proc 37 (2005) 1871
21. Chueh S.C., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen. incidence, risk factors, progression, and prognosis. Transplantation 76 (2003) 375
22. Morrisett J.D., Abdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 suppl 3 (2003) 143S
23. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
24. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 78 (2004) 1362
25. Mahe E., Morelon E., Lechaton S., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79 (2005) 476